SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.87
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sigma Healthcare is a retail pharmacy franchisor and full-line pharmaceutical wholesaler and distributor. Following its 2025 merger with Chemist Warehouse, its major pharmacy brands include Chemist Warehouse, Amcal and Discount Drug Stores.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.62

27 Aug
2026

-0.220

OPEN

$2.81

-7.75%

HIGH

$2.81

45,895,183

LOW

$2.59

TARGET
$3.163 20.7% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP . SK1 .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 6.2 7.1 xxx
DPS (cps) xxx 4.0 4.7 xxx
EPS Growth xxx 21.9% 14.3% xxx
DPS Growth xxx 100.0% 17.5% xxx
PE Ratio xxx N/A 38.0 xxx
Dividend Yield xxx N/A 1.8% xxx
Div Pay Ratio(%) xxx 64.8% 66.7% xxx

Dividend yield today if purchased 3 years ago: 5.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.49

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/03 - ex-div 2.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx6.2
DPS All xxxxxxxxxxxxxxx4.0
Sales/Revenue xxxxxxxxxxxxxxx10,835.0 M
Book Value Per Share xxxxxxxxxxxxxxx43.4
Net Operating Cash Flow xxxxxxxxxxxxxxx575.6 M
Net Profit Margin xxxxxxxxxxxxxxx6.55 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx14.67 %
Return on Invested Capital xxxxxxxxxxxxxxx10.62 %
Return on Assets xxxxxxxxxxxxxxx7.86 %
Return on Equity xxxxxxxxxxxxxxx14.67 %
Return on Total Capital xxxxxxxxxxxxxxx14.52 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx140.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx208 M
Long Term Debt xxxxxxxxxxxxxxx1,813 M
Total Debt xxxxxxxxxxxxxxx2,021 M
Goodwill - Gross xxxxxxxxxxxxxxx3,626 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx131 M
Price To Book Value xxxxxxxxxxxxxxx6.33

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx56.7 M
Capex % of Sales xxxxxxxxxxxxxxx0.52 %
Cost of Goods Sold xxxxxxxxxxxxxxx8,878 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx959 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx114 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

28/08/2026

1

Buy

$3.15

20.23%

On further inspection, the target price is lowered to $3.15 from $3.40 with a Buy retained. UBS sees ongoing sales strength in Chemist Warehouse Australia and International.

The company has scope to capitalise on structural tailwinds in back-of-store and health-and-beauty, the analyst explains. Gross margin expansion is flagged as well as improved operating leverage from cost management.

First read: Sigma Healthcare's FY26 EBIT and NPAT were slightly below UBS and consensus, with weaker cash conversion as inventory increased.

Chemist Warehouse Australia network sales rose 15.9% y/y, with LFL sales up 13.4% y/y, while international network sales increased 23.3% y/y.

Early FY27 trading has returned to double-digit LFL growth in Australian Chemist Warehouse stores, with Sigma expecting double-digit revenue and earnings growth in 1H27, broadly consistent with expectations.

Buy. Target $3.40.

FORECAST
UBS forecasts a full year FY27 dividend of 5.00 cents and EPS of 7.00 cents.
UBS forecasts a full year FY28 dividend of 6.00 cents and EPS of 8.00 cents.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

07/05/2026

1

Buy

$3.60

37.40%

Jarden reiterates its Buy rating and $3.60 target price for Sigma Healthcare after the company reported accelerating top-line sales growth and announced a capital-light entry into the UK market.

Domestic momentum remained strong through the second half, with Chemist Warehouse (AU) sales growth picking up to 17.1% year-on-year in March and April due to store expansions, share gains, and structural health tailwinds.

The broker views the new 75% joint venture with London-based GreenLight Pharmacy as a sensible expansion strategy, providing immediate access to 22 locations and existing licenses with zero initial equity cost.

This allows the company to deploy its Every Day Low Price (EDLP) and multi-buy model into an under-penetrated market where competitors currently charge premiums.

Earnings forecasts are maintained, though the broker notes modest upside risk to margin expectations as the company scales its operations and integrates its newly announced $40m New Zealand distribution centre.

FORECAST
Jarden forecasts a full year FY27 dividend of 4.60 cents and EPS of 7.70 cents.
Access Extra Coverage Research History >

SIG STOCK CHART

FNArena News on SIG

1
FNArena Corporate Results Monitor – 27-08-2026

Aug 27 2026 - Australia
2
Rudi’s View: Final Preparations For August

Aug 05 2026 - Rudi's View
3
Rudi’s View: Pre-August Picks In Resources, Retail & Small Caps

Jul 23 2026 - Rudi's View
4
Rudi’s View: Small Cap Favourites, AI & More

Jul 16 2026 - Rudi's View
5
Supermarkets Behemoths Remain In Focus

Jul 15 2026 - Australia

Latest Health & Nutrition News

1
The Defensive Proposition Of Sigma Healthcare

Mar 30 2026 - Australia
2
Sigma Healthcare’s Four Pillars Of Growth

Aug 29 2025 - Australia
3
Sigma Healthcare: Synergies, Margins In Focus

Jun 19 2025 - Australia
4
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
5
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
6
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
7
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
8
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
9
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
10
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI